CytomX Therapeutics, Inc. (CTMX) Stock Analysis
A live, multi-source view of CytomX Therapeutics, Inc. (CTMX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab.
Sector: Healthcare · Industry: Biotechnology · United States · 69 employees · cytomx.com
Key statistics · as of 2026-09-05
As of 2026-09-05, CytomX Therapeutics, Inc. (CTMX) had a market capitalization of $808.4M (forward -7.8) and a beta of 2.14; the shares traded in a 52-week range of $1.90 – $8.21 (61.4% over the year).
- Market cap
- $808.4M
- Enterprise value
- $483.8M
- Forward P/E
- -7.8
- Price / book
- 2.68
- EPS (trailing)
- $-0.57
- EPS (forward)
- $-0.47
- Payout ratio
- 0.0%
- 52-week range
- $1.90 – $8.21
- 52-week change
- 61.4%
- Beta
- 2.14
- Average volume
- 4.0M
- Shares outstanding
- 217.9M
- Short % of float
- 18.03%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, CytomX Therapeutics, Inc. (CTMX) last closed at $3.71 (the last completed close before that scan).
Technicals at the scan: RSI 60 (neutral territory), price +7.8% versus its 20-day average, 20-day versus 50-day average spread -1.1%, MACD histogram 0.05.
Sentiment inputs: StockTwits 94% bullish; analyst consensus score 84/100.
Next scheduled company event: in 58 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for CTMX in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
CTMX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls CytomX Therapeutics, Inc. (CTMX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell CTMX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.